Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

John Melo Biography and Net Worth

CEO of Amyris

John G. Melo serves as President, Chief Executive Officer, Director of the Company. Mr. Melo has served as our Chief Executive Officer and a director since January 2007 and as our President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum), one of the world’s largest energy firms, from 1997 to 2006, most recently as President of U.S. Fuels Operations. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, and Director of Global Brand Development. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of Renmatix, Inc., the Industrial and Environmental section of the Biotechnology Innovation Organization, and the California Life Sciences Association. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum.

What is John Melo's net worth?: The estimated net worth of John Melo is at least $0.00 as of July 6th, 2022. Mr. Melo owns 492,701 shares of Amyris stock worth more than $0 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Melo may own. Learn More about John Melo's net worth.
How do I contact John Melo?: The corporate mailing address for Mr. Melo and other Amyris executives is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. Amyris can also be reached via phone at (510) 450-0761 and via email at [email protected]. Learn More on John Melo's contact information.
Has John Melo been buying or selling shares of Amyris?: John Melo has not been actively trading shares of Amyris in the last ninety days. Most recently, John Melo sold 55,576 shares of the business's stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $2.12, for a transaction totalling $117,821.12. Following the completion of the sale, the chief executive officer now directly owns 492,701 shares of the company's stock, valued at $1,044,526.12. Learn More on John Melo's trading history.
Who are Amyris' active insiders?: Amyris' insider roster includes Eduardo Alvarez (COO), Anthony Hughes (CAO), Nicole Kelsey (Insider), Hermanus Kieftenbeld (CFO), Frank Kung (Director), James McCann (Director), and John Melo (CEO). Learn More on Amyris' active insiders.
Are insiders buying or selling shares of Amyris?: During the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 20,999 shares worth more than $19,949.05. The most recent insider tranaction occured on June, 2nd when CFO Hermanus Kieftenbeld sold 20,999 shares worth more than $19,949.05. Insiders at Amyris own 36.3% of the company. Learn More about insider trades at Amyris.
Information on this page was last updated on 6/2/2023.

John Melo Insider Trading History at Amyris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/6/2022	Sell	55,576	$2.12	$117,821.12	492,701
7/7/2021	Sell	95,115	$15.53	$1,477,135.95
2/19/2020	Sell	52,875	$3.41	$180,303.75	642,097
10/15/2018	Sell	5,195	$7.50	$38,962.50	743,713
7/16/2018	Sell	22,355	$6.61	$147,766.55	748,908
1/16/2018	Sell	10,776	$4.68	$50,431.68	83,172
6/5/2015	Sell	61,276	$2.00	$122,552.00
5/12/2015	Sell	65,575	$2.08	$136,396.00
5/24/2013	Sell	24,402	$2.85	$69,545.70
8/31/2012	Sell	668,730	$3.70	$2,474,301.00

John Melo Buying and Selling Activity at Amyris

Amyris Company Overview

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Today's Range

Now: N/A

50 Day Range

MA: $0.54

$0.05

$1.17

2 Week Range

Now: N/A

Volume

46,746,000 shs

Average Volume

12,593,118 shs

Market Capitalization

$18.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad